What the FDA labels say about taking them together
Gatifloxacin and milsaperidone
Milsaperidone's FDA label of February 27, 2026 names gatifloxacin in its warnings and precautions section; the gatifloxacin label PlainMeds reads does not name milsaperidone.
Check it at the source: the gatifloxacin FDA label on DailyMed (effective September 8, 2016, Allergan, Inc.); the milsaperidone FDA label on DailyMed (effective February 27, 2026, Vanda Pharmaceuticals Inc.).
What does the gatifloxacin label say about milsaperidone?
Gatifloxacin's label (effective September 8, 2016) does not name milsaperidone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (ZYMAXID), NDA022548 (Abbvie), as published by Allergan, Inc., effective September 8, 2016 (SPL set 1160b16c-929a-4e85-9c0b-1d8c96a7678b), via openFDA; the full label on DailyMed
What does the milsaperidone label say about gatifloxacin?
Milsaperidone label, warnings and precautionsSteps to Prevent or Mitigate Clinically Significant Adverse Reactions or Risks Associated with QTc Interval Prolongation The concomitant use of BYSANTI should be avoided with other drugs that prolong the QTc interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), antipsychotic drugs that prolong the QTc interval (e.g., chlorpromazine, thioridazine), antibiotics that prolong the QTc interval (e.g., gatifloxacin, moxifloxacin), or any other class of drugs known to prolong the QTc interval (e.g., pentamidine, levomethadyl acetate, methadone).
Source: FDA drug label (BYSANTI), Vanda Pharmaceuticals Inc., effective February 27, 2026 (SPL set 254a1c01-4a4c-4bdd-85d6-1f23f2e4e6f8), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Gatifloxacin | Milsaperidone | |
|---|---|---|
| Labeled for | n/a | Schizophrenia, Bipolar disorder |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $8.85 per mL 0.5% eye drops | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once